May 31, 2023 / 05:15PM GMT
Jonathan David Block - Stifel, Nicolaus & Company, Incorporated, Research Division - MD & Senior Equity Research Analyst
All right. Perfect. Great. Thanks. Good afternoon. Jon Block with Stifel. And we're transitioning to animal health in IDEXX. Thanks guys for joining us. We have with us Jay Mazelsky, President and CEO; and Brian McKeon, Executive Vice President and Chief Financial Officer.
Same sort of approach. I've been saying I've got a bunch of questions. Guys, if you have questions, please raise your hand or just shout out, and we'll get after them.
Questions and Answers:
Jonathan David Block - Stifel, Nicolaus & Company, Incorporated, Research Division - MD & Senior Equity Research AnalystI'm going to start with trends. And so we get a decent look on U.S. Vet volumes from other sources throughout the quarter, which seems highly correlated to your visits. And overall, U.S. clinical visits for IDEXX in 1Q '23 was basically flat. I think Brian you mentioned it, it weakened a bit exiting the quarter. But you talked about